Detection of SF3B1 p.Lys700Glu Mutation by PNA-PCR Clamping in Myelodysplastic Syndromes and Myeloproliferative Neoplasms
Authors:
- Jessica PetitiJessica Petiti
- Federico ItriFIFederico Itri
- Elisabetta SignorinoESElisabetta Signorino
- Antonio FrolliAFAntonio Frolli
- Carmen FavaCFCarmen Fava
- Marco ArmenioMAMarco Armenio
- Silvia MariniSMSilvia Marini
- Emilia GiuglianoEGEmilia Giugliano
- Marco Lo IaconoMIMarco Lo Iacono
- Giuseppe SaglioGSGiuseppe Saglio
- Daniela CilloniDCDaniela Cilloni
Open Access
- 25 February 2022
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (5) , 1267
Abstract
Mutations in SF3B1 are found in 20% of myelodysplastic syndromes and 5–10% of myeloproliferative neoplasms, where they are considered important for diagnosis and therapy decisions. Sanger sequencing and NGS are the currently available methods to identify SF3B1 mutations, but both are time-consuming and expensive techniques that are not practicable in most small-/medium-sized laboratories. To identify the most frequent SF3B1 mutation, p.Lys700Glu, we developed a novel fast and cheap assay based on PNA-PCR clamping. After setting the optimal PCR conditions, the limit of detection of PNA-PCR clamping was evaluated, and the method allowed up to 0.1% of mutated SF3B1 to be identified. Successively, PNA-PCR clamping and Sanger sequencing were used to blind test 90 DNA from patients affected by myelodysplastic syndromes and myeloproliferative neoplasms for the SF3B1 p.Lys700Glu mutation. PNA-PCR clamping and Sanger sequencing congruently identified 75 negative and 13 positive patients. Two patients identified as positive by PNA-PCR clamping were missed by Sanger analysis. The discordant samples were analyzed by NGS, which confirmed the PNA-PCR clamping result, indicating that these samples contained the SF3B1 p.Lys700Glu mutation. This approach could easily increase the characterization of myelodysplastic syndromes and myeloproliferative neoplasms in small-/medium-sized laboratories, and guide patients towards more appropriate therapy.Keywords
Funding Information
- Fondazione Italiana per la Ricerca sul Cancro (23344)
This publication has 35 references indexed in Scilit:
- Biologic and clinical significance of somatic mutations of SF3B1 in myeloid and lymphoid neoplasmsBlood, 2013
- Emerging roles of the spliceosomal machinery in myelodysplastic syndromes and other hematological disordersLeukemia, 2012
- Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasmsBlood, 2011
- SF3B1, a splicing factor is frequently mutated in refractory anemia with ring sideroblastsLeukemia, 2011
- Ring sideroblasts and sideroblastic anemiasHaematologica, 2011
- A comparability study of 5 commercial KRAS testsDiagnostic Pathology, 2010
- Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencingNature Genetics, 2008
- Significant Correlation Between the Degree of WT1 Expression and the International Prognostic Scoring System Score in Patients With Myelodysplastic SyndromesJournal of Clinical Oncology, 2003
- PNA hybridizes to complementary oligonucleotides obeying the Watson–Crick hydrogen-bonding rulesNature, 1993
- Sequence-Selective Recognition of DNA by Strand Displacement with a Thymine-Substituted PolyamideScience, 1991